Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

SerenOx Africa aims to address diagnostic gaps for common blood disorders through a testing facility for key underserved patient populations in Tanzania. This facility will also aim to provide early cancer detection for high-risk patients.

Commenting on the launch, Professor Anna Schuh, Director of Molecular Diagnostics in the Department of Oncology, said: ‘A precise diagnosis is essential in delivering the right treatment to the right patient and at the right time, however 47% of the global population has little to no access to diagnostics. When it comes to common and potentially curable diseases like some types of anaemia or cancers, a late diagnosis or a misdiagnosis majorly contributes to these diseases’ poor outcomes.’

In sub-Saharan Africa, many diseases that can be easily cured or well controlled with affordable therapies are currently not being diagnosed. For early-stage cancer – adds Schuh - over 90% of patients can be cured in-country with treatment that costs a fraction of those for late-stage cancer.

In partnership with its sister company - Seren (UK) - SerenOx Africa ultimately aims to expand its services to the rest of Africa. A social enterprise spin-out from the University of Oxford, Seren (UK) makes use of research from the University to create revenue streams that support the establishment of diagnostics in low- and middle-income countries through training and capacity building.

The initiative was enabled by Schuh, building on 18-years’ experience developing genetic tests for blood diseases and cancer: ‘I realised that what we’re doing in the UK is chipping away at the edges with more personalised testing which improve outcomes for a few people. Important as that is for those individuals, my experience in East Africa made me see that developing diagnostic services alongside access programmes to therapies in areas where these are scarce has the potential to transform millions of lives.’ 

Read more about Seren (UK) on the University website

Similar Stories

Crowd-sourcing approach assesses current methods for improved automated detection and boundary mapping of colorectal cancer precursors

A computer vision challenge was set to objectively quantify the generalisability of polyp detection and mapping algorithms, and challenge participants to innovate novel methods.